The global clinical trials market reached between USD 64.94 billion and USD 90.44 billion in 2025, depending on scope, with Fortune Business Insights projecting USD 69.27 billion in 2026 and USD 120.75 billion by 2034 at a 7.20% CAGR. North America holds 43.90% to 50.7% of revenue. IQVIA leads with over 14% share. This post covers market size, regions, phases, and drug development economics.
Clinical Trials Market Statistics – TL;DR
- The global clinical trials market is forecast at USD 69.27 billion in 2026, per Fortune Business Insights.
- North America held a 43.90% revenue share in 2025, valued at USD 28.54 billion.
- Phase III studies account for 46.95% of the market and average USD 282 million per US trial.
- Oncology represents 29.67% of clinical trial spend in 2026, the largest therapeutic segment.
- The top five CROs — IQVIA, LabCorp, ICON plc, Parexel, and Syneos Health — hold 45% of global revenue.
The market splits into two scope buckets. Lower-end firms such as Fortune Business Insights, Global Market Insights, and MarketsandMarkets size the outsourced CRO market at USD 64–67 billion in 2025. Higher-end firms count internal pharma research alongside outsourced spend, landing at USD 87–90 billion.
How Big Is The Clinical Trials Market In 2026?
Six research firms put 2025 base values between USD 64.94 billion and USD 90.44 billion. The spread reflects scope, not disagreement on growth — every firm projects a forecast CAGR between 6.30% and 8.9%.
| Research Firm | 2025 Value | 2026 Projected | Forecast End | CAGR |
|---|---|---|---|---|
| Fortune Business Insights | USD 64.94B | USD 69.27B | USD 120.75B (2034) | 7.20% |
| Global Market Insights | USD 66.3B | USD 70.7B | USD 144.4B (2035) | 8.3% |
| MarketsandMarkets | USD 66.59B | — | USD 101.86B (2030) | 8.9% |
| Grand View Research | USD 89.0B | USD 94.0B | USD 158.4B (2033) | 7.7% |
| Mordor Intelligence | USD 90.44B | USD 95.97B | USD 131.55B (2031) | 6.51% |
| SNS Insider | USD 87.30B | — | USD 160.82B (2035) | 6.30% |
Source: Fortune Business Insights, Global Market Insights, MarketsandMarkets, Grand View Research, Mordor Intelligence, SNS Insider
The Fortune Business Insights CAGR verification holds: USD 69.27B compounded at 7.20% over eight years reaches roughly USD 120.6B, matching the reported USD 120.75B forecast for 2034. IQVIA and other major contract research organisations operate primarily within the outsourced-services portion of this market.
Clinical Trials Market Statistics By Region
North America led 2025 revenue. Fortune Business Insights put the regional share at 43.90% (USD 28.54 billion), while Grand View Research and Global Market Insights placed it closer to 50.7%. The gap traces to scope rather than geography.
| Region | 2025 Size | 2026 Projected | Share |
|---|---|---|---|
| North America | USD 28.54B | USD 30.27B | 43.90% |
| Europe | USD 21.84B | USD 23.10B | 33.60% |
| Asia Pacific | USD 12.53B | USD 13.71B | 19.30% |
| Rest of World | ~USD 2.03B | ~USD 2.13B | ~3.20% |
Source: Fortune Business Insights
Asia Pacific posts the fastest growth across all five firms reporting regional CAGRs. China is projected at USD 3.87 billion in 2026, India at USD 3.24 billion, and Japan at USD 2.81 billion. The US alone is projected at USD 26.25 billion in 2026.
Top Countries By 2026 Market Size
| Country | 2026 Projected |
|---|---|
| United States | USD 26.25B |
| Germany | USD 4.51B |
| United Kingdom | USD 4.10B |
| China | USD 3.87B |
| India | USD 3.24B |
| Japan | USD 2.81B |
Source: Fortune Business Insights
Clinical Trials Market Statistics By Phase
Phase III studies command the largest share of clinical trial spend. Fortune Business Insights puts Phase III at 46.95% of 2026 revenue. Grand View Research reports 53.6% for 2025.
The Congressional Budget Office reported an average US Phase III trial cost of USD 282 million per study. Phase II posts the fastest CAGR across forecasts. SNS Insider attributes 55% of total expenditure to Phase III. ICON plc and Parexel rank among the firms most exposed to Phase III outsourcing volume.
Clinical Trials Market Statistics By Therapeutic Area
Oncology leads. Fortune Business Insights reports a 29.67% share in 2026, and Mordor Intelligence reports 29.70% in 2025 — a rare cross-firm match. SNS Insider notes that oncology accounts for more than 35% of all ongoing trials globally.
| Therapeutic Area | 2026 Share / CAGR | Notes |
|---|---|---|
| Oncology | 29.67% share | Largest application segment |
| CNS / Neurology | 9.10% CAGR | Fastest-growing application (2026–2031) |
| Cardiology | 4.6% CAGR | — |
| Clinical trial monitoring | 28.50% of spend | Service-line share, 2025 |
Source: Fortune Business Insights; Mordor Intelligence; SNS Insider
The decentralised clinical trials sub-market is sized at USD 8.8 billion in 2025 and projected at USD 18.8 billion by 2030, a 13.7% CAGR. The CTMS sub-market — clinical trial management systems — grows at 13.9% CAGR from USD 2.08 billion in 2025 to USD 4.01 billion by 2030.
Drug Development Costs And FDA Approval Rates
The Tufts Center for the Study of Drug Development reports an average drug development cost of USD 2.60 billion per approved medicine, including the cost of failures. Only 12% of drug candidates entering clinical trials secure FDA approval.
The math: each approved medicine effectively funds the costs of roughly eight failed candidates in the same pipeline. Pfizer reported USD 10,822 million in R&D spend in 2024, up 1.3% from 2022. Novartis reported approximately USD 10,022 million the same year.
| Metric | Figure |
|---|---|
| Average drug development cost | USD 2.60 billion |
| FDA approval rate for candidates entering trials | 12% |
| Average US Phase III spend per trial | USD 282 million |
| Pfizer R&D (2024) | USD 10,822 million |
| Novartis R&D (2024) | ~USD 10,022 million |
| EFPIA pharma R&D (2022) | USD 46,792.8 million (+7.2% YoY) |
Source: Tufts Center for the Study of Drug Development; Congressional Budget Office; EFPIA; Pfizer and Novartis filings
Top CRO Companies By Market Share
IQVIA leads with over 14% of global revenue in 2025. The top five firms — IQVIA, LabCorp, ICON plc, Parexel, and Syneos Health — collectively hold 45%, per Global Market Insights.
Pharma and biopharma sponsors fund 68% of the industry. Government and non-profit funders are growing at 7.50% CAGR through 2031. June 2024 brought a Thermo Fisher Scientific partnership with the NCI on AML and MDS research, IQVIA’s “One Home for Sites” platform launch, and LabCorp’s “Global Trial Connect” lab service. Syneos Health rounds out the top five.
Clinical Trials Market Statistics: Global Activity
SNS Insider counts over 450,000 registered clinical studies across 220 countries. The WHO recorded an 11.7% year-over-year increase in global trial activity in 2021 versus 2020. The WHO reported in March 2024 that one in three people globally are affected by neurological disorders, supporting demand growth in the CNS segment.
FAQs
How big is the clinical trials market in 2026?
Fortune Business Insights projects the global clinical trials market at USD 69.27 billion in 2026, rising to USD 120.75 billion by 2034 at a 7.20% CAGR. Grand View Research reports a higher 2026 figure of USD 94.0 billion under a wider scope.
Which region leads the clinical trials market?
North America led with a 43.90% share in 2025, valued at USD 28.54 billion per Fortune Business Insights. Grand View Research and Global Market Insights report a 50.7% share. Asia Pacific posts the fastest CAGR across all firms.
What is the average cost to develop a new drug?
The Tufts Center for the Study of Drug Development reports an average cost of USD 2.60 billion per approved medicine, including the cost of failed candidates. Only 12% of drug candidates entering trials secure US FDA approval.
Who is the largest CRO by market share?
IQVIA leads with over 14% of global clinical trials market revenue in 2025, per Global Market Insights. The top five firms — IQVIA, LabCorp, ICON plc, Parexel, and Syneos Health — together hold 45% of global revenue.
What share of the market does oncology represent?
Oncology accounts for 29.67% of clinical trial revenue in 2026 per Fortune Business Insights, and 29.70% in 2025 per Mordor Intelligence. SNS Insider reports oncology makes up more than 35% of all ongoing trials globally.
Sources
https://www.fortunebusinessinsights.com/clinical-trials-market-103197
https://www.gminsights.com/industry-analysis/clinical-trials-market
https://www.snsinsider.com/reports/clinical-trials-market-2691
